Colinz Laboratories (531210.BO) Stock Price

Colinz Laboratories Price

CLOSED
65.50
​
Market closed

Revenue at Colinz Laboratories has contracted by 0.5% per year over the past 14 years to 61.36 M INR. Earnings per share have grown at 16.5% per year over the last 14 years. Colinz Laboratories's net margin stands at 8.4%, up from 4.9% several years earlier.

Colinz Laboratories stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Colinz Laboratories business model & stock analysis

Colinz Laboratories Ltd manufactures pharmaceutical formulations including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company markets allopathic and ayurvedic products targeting hypertension, cholesterol, diabetes, piles, pyrexia, and malaria treatments for physicians. Gynecologists receive specialized products for morning sickness, infertility, IUGR, and pregnancy maintenance. Additional offerings include hematinic, antispasmodic, anti-inflammatory/anti-allergic tablets, capsules, gel, and medicated shampoo. Products are sold across Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal through the company's own marketing team. The firm's revenue streams come from direct sales to healthcare professionals and pharmacies within its operational states. Physicians prescribe products for chronic conditions like hypertension and diabetes, while gynecologists utilize specialized treatments for pregnancy-related issues. The company's product portfolio spans both conventional allopathic medicines and traditional ayurvedic formulations, catering to diverse medical needs. Marketing efforts focus on state-specific distribution through dedicated in-house sales staff. Colinz Laboratories Ltd serves the pharmaceutical market segment with a clear focus on regional healthcare providers. Its product range addresses common health concerns such as cardiovascular issues, metabolic disorders, and pregnancy care. The company's strategy involves direct engagement with medical practitioners to promote its formulations, ensuring consistent market presence in key Indian states without external partnerships or third-party distribution channels.

Frequently asked questions about Colinz Laboratories

Converted at the current exchange rate, the Colinz Laboratories share trades at 0.64 EUR (65.50 INR).

The revenue of Colinz Laboratories is 61.36 M INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Colinz Laboratories is 5.15 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Colinz Laboratories is currently 32.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Colinz Laboratories stock.

The price-to-sales ratio (P/S) of Colinz Laboratories is currently 2.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Colinz Laboratories stock.

The Eulerpool Quality Score for Colinz Laboratories is 2/10.

The ISIN of Colinz Laboratories is INE923C01011. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Colinz Laboratories is 531210.BO. The ticker symbol is used to trade Colinz Laboratories shares on the stock exchange.

Fair ValueTerminal
64.85 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website colinz.com
Country
Currency
INR
Initial public offering
Jan 13, 2004
ISIN
INE923C01011
Cusip
Y1674A111
Market capitalization
165.06 M INRMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
65.68
P/B Ratio
1.64
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5.12 %
Last updated Nov 19, 2026, 10:18 PM

Colinz Laboratories Peer Group

Colinz Laboratories FIGI

CLZ:IN · BBG000BGWY38CLZ:IB · BBG000BGWYF5